4.7 Review

Traditional Chinese Medicine for Cardiovascular Disease Evidence and Potential Mechanisms

期刊

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 69, 期 24, 页码 2952-2966

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2017.04.041

关键词

Chinese herbal drugs; dyslipidemia; heart failure; hypertension; randomized controlled trials as topic; type 2 diabetes mellitus

资金

  1. National 973 Basic Research Program of China [2013CB530703, 2015CB553604]
  2. National Natural Science Foundation of China [81400284, 81425004, 91339109, 81270350]
  3. Program of Introducing Talents of Discipline to Universities [B07035]
  4. State Key Program of National Natural Science of China [61331001, 81530014]
  5. International Collaboration and Exchange Program of China [81320108004]
  6. Natural Science Foundation of Shandong Province [ZR2014HM044, ZR2014HP045]
  7. Clinical Medicine Science and Technology Innovation Plan of Jinan Science and Technology Bureau [201602157, 201506002]
  8. Shenzhen Science and Technology Research and Development Fund [JCYJ20160331183804137]

向作者/读者索取更多资源

Traditional Chinese medicine (TCM) has more than 2,000 years of history and has gained widespread clinical applications. However, the explicit role of TCM in preventing and treating cardiovascular disease remains unclear due to a lack of sound scientific evidence. Currently available randomized controlled trials on TCM are flawed, with small sample sizes and diverse outcomes, making it difficult to draw definite conclusions about the actual benefits and harms of TCM. Here, we systematically assessed the efficacy and safety of TCM for cardiovascular disease, as well as the pharmacological effects of active TCM ingredients on the cardiovascular system and potential mechanisms. Results indicate that TCM might be used as a complementary and alternative approach to the primary and secondary prevention of cardiovascular disease. However, further rigorously designed randomized controlled trials are warranted to assess the effect of TCM on long-term hard endpoints in patients with cardiovascular disease. (C) 2017 by the American College of Cardiology Foundation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据